Multinational phase 3 trial of trifluridine-tipiracil with or without bevacizumab for refractory metastatic colorectal cancer

The multinational phase 3 SUNLIGHT trial evaluated addition of bevacizumab to trifluridine-tipiracil (FTD-TPI) for refractory metastatic colorectal cancer. The median overall survival was 10.8 months with bevacizumab plus FTD-TPI versus 7.5 months with FTD-TPI alone (HR 0.61; p<0.001) while the median progression-free survival was 5.6 months versus 2.4 months (HR 0.44; p<0.001), and the median time to worsening of the ECOG performance status score from 0 or 1 to 2 or more was 9.3 months versus 6.3 months (HR 0.54; 95% CI 0.43-0.67). Addition of bevacizumab to FTD-TPI was tolerated. There were no new safety concerns (quick take video summary).